TRVN To Report Data In Mid-year, TSHA Trims Workforce, FDA Decision On SPRO's NDA To Be Delayed?

Spero Therapeutics Inc. (SPRO), whose New Drug Application for Tebipenem HBr is under regulatory review in the U.S., has been notified by the FDA of certain deficiencies in the application. The company aims to engage with the FDA to resolve the deficiencies as quickly as possible.

from RTT - Top Story https://ift.tt/CuAqBXL
via IFTTT